Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Cold-fx. (Kevin Van Paassen/Kevin Van Paassen/The Globe and Mail)
Cold-fx. (Kevin Van Paassen/Kevin Van Paassen/The Globe and Mail)

Valeant takes control of Afexa, extends bid Add to ...

Valeant Pharmaceuticals International Inc. says it has acquired nearly 81 million shares of Cold-FX maker Afexa Life Sciences Inc., or nearly 74 per cent of the Edmonton drug maker, under a friendly takeover offer.

Valeant said Tuesday it will extend its bid to Oct. 27 to acquire the rest of the shares and privatize Afexa.

More related to this story

The Toronto-area drug maker, formerly known as Biovail, wants to buy Afexa to expand the company's flu treatment sales globally.

Follow us on Twitter: @GlobeInvestor

 
  • VRX-T
  • FXA-T
Live Discussion of VRX on StockTwits
More Discussion on VRX-T
Live Discussion of FXA on StockTwits
More Discussion on FXA-T

More related to this story

Topics:

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories